Canadian Hematology Paper of the Year Award

Canadian Hematology

Paper of the Year Awards

Each year, the Canadian Hematology Society invites its members to nominate “the best hematology paper in Canada”, published between September 1st of the previous year and August 31 of the current year. The award, selected by a review committee, is presented at the CHS Awards ceremony at the Annual Meeting held at ASH each December.

Recent winners have published in prestigious journals such as Nature, The Lancet and The New England Journal of Medicine, papers with exceptional impact that represent the best of Canadian hematology research.

Nominated individuals must be CHS members in good standing. Papers addressing either clinical or lab-based hematology research are considered.

Deadline: September 15th

Application Form

2023

Paper of the Year: Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma | Nature Medicine

Published: Nature Medicine, August 31, 2023 DOI https://doi.org/10.1038/s41591-023-02491-5

Author(s): Dr. Holly Lee, et al

2021

Paper of the Year: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 / Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Published: The New England Journal of Medicine, August 4, 2021 N at NEJM.org. DOI:10.1056/NEJMoa2105911 and DOI:10.1056/NEJMoa2103417

Author(s): Dr. Zarychanski, et al

2020

GO TO PAPER

Paper of the Year: Diagnosis of Pulmonary Embolism with D-Dimer Adjusted to Clinical Probability

Published: The New England Journal of Medicine, October 30, 2020 N Engl J Med 2019; 381:2125-2134

Author(s): Clive Kearon, M.B., Ph.D., et al

2019

GO TO PAPER

Paper of the Year: The Mitochondrial Transacylase, Tafazzin,
Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids

Published:Cell Stem Cell VOLUME 24, ISSUE 4, P621-636.E16, APRIL 04, 2019 March 28, 2019DOI: https://doi.org/10.1016/j.stem.2019.02.020

Author(s): Ayesh K. Seneviratne, et al

2018

GO TO PAPER

Paper of the Year: Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty

Published: The New England Journal of Medicine February 22, 2018 vol. 378: 699-707

Author(s): David R. Anderson, M.D., et al

Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health Authority

2017

GO TO PAPER

Paper of the Year: A 17-gene stemness score for rapid determination of risk in acute leukemia

Published: Nature 2016; 540:433-437; 15 December 2016

Author(s): Stanley W.K. Ng, et al

University of Toronto and Princess Margaret Cancer Centre
University Health Network, Toronto

2016

GO TO PAPER

Paper of the Year: Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Published: The LANCET, 17, February, 2016

Author(s): Irwin Walker MD

Professor of Medicine, McMaster University
Juravinski Hospital and Cancer Centre

2015

GO TO PAPER

Paper of the Year: Screening for Occult Cancer in Unpro-voked Venous Thromboembolism

Published: New England Journal of Medicine June 22, 2015, at NEJM.org

Author(s): Dr. Marc Carrier

The Ottawa Hospital

2014

GO TO PAPER

Translational/Basic Category Paper of the Year: Identification of pre-leukaemic Haematopoietic stem cells in acute leukaemia

Published: Nature, Volume: 506, Pages: 328–333 (20 February 2014)

Author(s): Liran I Shlush MD PhD

Ontario Cancer Institute, Toronto Canada
Clinical Fellow Leukemia Service
Princess Margaret Cancer Center, Toronto, Canada

GO TO PAPER

Clinical Category Paper of the Year: Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial

Published: The Lancet, Volume 384, Issue 9955, Pages 1673 – 1683 (8 November 2014)

Author(s): M A Rodger MD

Thrombosis Program, Division of Hematology
Department of Medicine, University of Ottawa
Ottawa Hospital Research Institute, Ottawa, ON, Canada